HAT01H

HAT01H is a novel topical treatment developed by Haus Bioceuticals for eczema and atopic dermatitis (AD), which are chronic inflammatory skin diseases characterized by impaired epidermal barrier function and pruritic eczematous plaques. The drug has demonstrated safety and significant efficacy in clinical studies, with reports of controlling signs and symptoms in 85% of patients with AD. HAT01H is positioned as a safer anti-inflammatory alternative to traditional therapies like topical corticosteroids and calcineurin inhibitors, which have notable long-term side effects. Clinical trials have evaluated its use in moderate to severe atopic dermatitis, as well as its dermatological safety profile.